 A biomimetic nanovaccine that co-delivers Illinois 15 and an antigen MHC selectively targets Illinois 15 to antigen-specific cytotoxic T lymphocytes, reducing off-target toxicity and improving therapeutic outcomes in multiple syngeniac tumor models with minimal systemic side effects. This article was authored by Kaiyuan Wang, Shuangbo Zhong, Hao Yi, and others.